Publications & posters

Publication ACOP15, Dec 04, 2024

Coupling a QSP model with a simple statistical layer to predict asthma exacerbation rate reduction from allergen challenge results

Théo Galland, Cristhyne Leon, Caterina Sansone, Anne Vaslin Chessex, Christian Pasquali, Lorenz Lehr, Alexander Kulesza, Simon Arsène
Learn more
Publication ACOP15, Dec 04, 2024

Towards a computational QSP platform to support ADC design in cancer

Théo Galland, Claire Couty, Brian Topp, Jim Bosley, Simon Arsène, Asher Hussain, Lara Bruzière
Learn more
Publication ACOP15, Dec 04, 2024

Towards a QSP platform to support drug development in hematological cancers

P. Lemarre, A. Toledo, A. Schneider, M. Hanke, A. Kulesza, S. Arsène, B. Zhao, F. Alemdehy, L. Koopman, T. Li, N. Afzal, C. Thalhauser, J. Bosley, C. Couty
Learn more
Publication ACOP15, Dec 04, 2024

Mathematical modeling can help to successfully translate preclinical findings in mice models of asthma into first-in-human trials

Cristhyne Leon, Théo Galland, Caterina Sansone, Anne Vaslin Chessex, Christian Pasquali, Lorenz Lehr, Alexander Kulesza, Simon Arsène
Learn more
Publication ACOP15, Dec 04, 2024

A within-host dynamic model of B. pertussis to support vaccine development

Hippolyte Darré, Juan C. Vargas-Zambrano, Markus Rehberg, Britta Wagenhuber, Pascal Blanc, Alain Sabouraud, Denis Macina, Laurent Coudeville, Simon Arsène
Learn more
Publication ACOP15, Dec 04, 2024

Dissecting Bcl-2 Sensitivity in AML: A QSP Model for Venetoclax-Azacitidine Therapy

Matthias Hanke, Satoshi Nakayama, Tomohisa Nakada, Claire Couty, Simon Arsène
Learn more
Publication ACOP15, Dec 04, 2024

Combining a Quantitative Systemic Pharmacology (QSP) model of NSCLC with an existing KPD model of Gemcitabine: a first step towards a new paradigm in clinical trials simulation

Eléa Thibault-Greugny, Nicolas Ratto, Loic Ethève, Simon Arsène, Jim Bosley, Jean-Pierre Boissel, Nicholas Holford, Adèle L'Hostis, Claudio Monteiro
Learn more
Publication ACOP15, Dec 04, 2024

Leveraging AI for improved reproducibility of mathematical disease models: insights from a retinitis pigmentosa case study

Elea Thibault Greugny, Nicolas Ratto, Loic Etheve, Jean-Baptiste Gourlet, Simon Arsène, Jim Bosley, Frederic Cogny, Claudio Monteiro
Learn more
Poster ACC 2024, Oct 31, 2024

Validation of an in-silico knowledge-based mechanistic model of atherosclerotic cardiovascular disease for the SIRIUS study

D. Angoulvant, P. Amarenco, A. Bastien, E. Bechet, F. Boccara, JP Boissel, B. Cariou, E. Courcelles, A. Diatchenko, S. Granjeon-Noriot, G. Mahé, E. Peyronnet, L. Portal, S. Porte, Y. Wang, P.G Steg
Learn more
Poster ASCO2024, Jun 07, 2024

Prospective validation of in silico clinical trials prediction using an EGFR-mutated NSCLC mechanistic computational disease model

M. Duruisseaux, P. Masson, A. Nativel, N. Girard, J. Cadranel, A. Swalduz, M. Coudron, G. Bouchard, R. Kahoul, E. Jacob, J. Bosley, JL. Palgen, A. L'Hostis, C. Monteiro
Learn more
Publication jacionline (february 16, 2024) DOI:https://doi.org/10.1016/j.jaci.2023.12.031, May 31, 2024

A quantitative systems pharmacology workflow toward optimal design and biomarker stratification of atopic dermatitis clinical trials

Natacha Go, Simon Arsène, Igor Faddeenkov, Théo Galland, Shiny Martis B., Diane Lefaudeux, Yishu Wang, Loic Etheve, Evgueni Jacob, Claudio Monteiro, Jim Bosley, Caterina Sansone, Christian Pasquali, Lorenz Lehr, Alexander Kulesza,
Learn more
Publication MDPI Biomedicines 2024 (21 March 2024) 12(3), 704; https://doi.org/10.3390/biomedicines12030704, May 31, 2024

Comparing the Efficacy of Two Generations of EGFR-TKIs: An Integrated Drug–Disease Mechanistic Model Approach in EGFR-Mutated Lung Adenocarcinoma

by Hippolyte Darré, Perrine Masson, Arnaud Nativel, Laura Villain, Diane Lefaudeux, Claire Couty, Bastien Martin, Evgueni Jacob, Michaël Duruisseaux, Jean-Louis Palgen, Claudio Monteiro and Adèle L’Hostis
Learn more
Poster EAS 2024, May 30, 2024

Predicting the efficacy of Inclisiran on cardiovascular outcomes in patients with established atherosclerotic cardiovascular disease: primary results of the in silico SIRIUS trial

D. Angoulvant, P.Amarenco, A.Bastien, E. Bechet, F. Boccara, JP. Boissel, B. Cariou, E. Courcelles, A. Diatchenko, A. Filipovics, S. Granjeon-Noriot, R. Kahoul, G. Mahé, E. Peyronnet, L. Portal, S. Porte, Y. Wang, P.G. Steg
Learn more
Publication ISPOR-Europe23, Nov 30, 2023

In Silico Clinical Trials Using Mechanistic Knowledge-Based Model, an Innovative Approach to Accelerate Data Generation and Support Health Technology Assessment

E. Pham, S. Porte, E. Courcelles, E. Peyronnet, Y. Wang, A. Diatchenko, G.Gomez, P. Amarenco, D. Angoulvant, F. Boccara, B. Cariou, G. Mahé, N. Marquet, A. Bastien, L. Portal, JP. Boissel, E. Bechet, S. Granjeon-Noriot, P.G. Steg
Learn more
Poster ACOP 23, Nov 10, 2023

A multiscale model of atherosclerotic cardiovascular disease to predict lipid lowering therapies effect on clinical events

S. Porte, E. Courcelles, E. Peyronnet, Y. Wang, P. Amarenco, D. Angoulvant, F. Boccara, B. Cariou, G. Mahé, P.G. Steg, A. Bastien, L. Portal, L. Bruziere, E. Bechet, S. Granjeon-Noriot
Learn more
Publication BMC Bioinformatics 24, no. 1 (September 4, 2023). https://doi.org/10.1186/s12859-023-05430-w, Sep 11, 2023

Empirical methods for the validation of time-to-event mathematical models taking into account uncertainty and variability: application to EGFR + lung adenocarcinoma

Evgueni Jacob, Angélique Perrillat-Mercerot, Jean-Louis Palgen, Adèle L’Hostis, Nicoletta Ceres, Jean-Pierre Boissel, Jim Bosley, Claudio Monteiro, Riad Kahoul
Learn more
Publication Nature: npj Syst Biol Appl 9, 37 (2023). https://doi.org/10.1038/s41540-023-00292-7, Sep 11, 2023

Knowledge-based mechanistic modeling accurately predicts disease progression with gefitinib in EGFR-mutant lung adenocarcinoma

Adèle L’Hostis, Jean-Louis Palgen, Angélique Perrillat-Mercerot, Emmanuel Peyronnet, Evgueni Jacob, James Bosley, Michaël Duruisseaux, Raphaël Toueg, Lucile Lefèvre, Riad Kahoul, Nicoletta Ceres, Claudio Monteiro
Learn more
Poster ESC Congress 2023, Aug 25, 2023

Design of a knowledge-based mechanistic model of atherosclerotic cardiovascular disease for in silico trials

D. Angoulvant1, P. Amarenco2, A. Bastien3, E. Bechet4, F. Boccara5, JP. Boissel4, B. Cariou6, E. Courcelles4, S. Granjeon-Noriot4, G. Mahé7, E. Peyronnet4, L. Portal3, S. Porte4, Y. Wang4, P.G. Steg8
Learn more
Poster AACR 2023, May 11, 2023

Exploring the impact of assuming spherical tumors on the modeled clinical outcome through the analysis of tumor measurements and in silico simulations

J. Kleine-Schultjann1, G. Gómez1, A. L'Hostis1, J-L. Palgen1, C. Monteiro1, P. Masson1
Learn more
Poster AACR 2023, May 11, 2023

The combination of statistical methods to compare observed and simulated data allowed to assess effectively the validity of mathematical model predictions in a context of a EGFR+ Lung Adenocarcinoma

Evgueni Jacob1, Laura Villain1, Nicoletta Ceres1, Jean-Louis Palgen1, Adèle L'Hostis1, Claudio Monteiro1, Riad Kahoul1
Learn more
Poster AACR 2023, May 11, 2023

Simulations of tumor heterogeneity impact on treatment response using a mechanistic model of EGFR-mutant lung adenocarcinoma

P Masson1, C Couty1, A Nativel1, E Jacob1, R Toueg2, M Duruisseaux3, A L’Hostis1, JL Palgen1, C Monteiro1
Learn more
Poster AACR 2023, May 11, 2023

Comparison of the effect of two EGFR-TKI in patients with EGFR-mutant lung adenocarcinoma using in silico clinical trials

H. Darré1, B. Martin1, F. Hammami1, A. Nativel1, D. Lefaudeux1, R. Toueg2, M. Duruisseaux3, J-L. Palgen1, P. Masson1, A. L’Hostis1, N. Ceres1, C. Monteiro1
Learn more
Poster ASCPT 2023, Apr 05, 2023

Effectiveness of high dose versus standard dose influenza vaccines in older adults : insights from a multi-strain modeling approach

Urdy, S.; Ratto, N.; Hanke, M.; Toledo, A. I.; Peyronnet, E.; Jacob, E.; Thommes, E.; Chaves, S.; Coudeville, L.; Boissel, J. P.; Bruezière, L. and Courcelles, E.
Learn more
Poster 4th European Conference on Pharmaceutics, Mar 28, 2023

Characterization of optimal clinical trial design and best responders characteristics using mechanistic modeling Application to Chronic HBV

Solène Granjeon-Noriot, Anne Schneider, Solène Porte, Emmanuel Peyronnet, Pietro Scalfaro, Emmanuel Pham, Lara Bruezière
Learn more
Publication NATURE REVIEWS, Oct 07, 2022

Predictive validity in drug discovery: what it is, why it matters and how to improve it

Jack W. Scannell, James Bosley, John A.Hickman, Gerard R. Dawson, Hubert Truebel, Guilherme S. Ferreira, Duncan Richards and J.Mark Treherne
Learn more
Poster VPH Conference, Sep 09, 2022

Integration of heterogeneous biological data in multiscale mechanistic model calibration

Jean-Louis Palgen, Angélique Perrillat-Mercerot, Nicoletta Ceres, Emmanuel Peyronnet, Matthieu Coudron, Jim Bosley, Adèle L'Hostis, Claudio Monteiro
Learn more
Poster VPH Conference, Sep 09, 2022

Building a cloud simulation system for reproducible and multi-level cached in-silico trials

Eliott Tixier, Matthieu Coudron, Yves Parès
Learn more
Poster ERS Conference, Sep 06, 2022

Viral kinetic modeling and simulation of the impact of non-pharmaceutical COVID-19 interventions in different countries: model-informed respiratory disease trial design

Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Publication Acta Biotheoretica, Jul 07, 2022

Integration of Heterogeneous Biological Data in Multiscale Mechanistic Model Calibration: Application to Lung Adenocarcinoma

Jean‑Louis Palgen, Angélique, Perrillat‑Mercerot, Nicoletta Ceres, Emmanuel Peyronnet, Matthieu Coudron, Eliott Tixier, Ben M. W. Illigens, Jim Bosley, Adèle L’Hostis, Claudio Monteiro
Learn more
Poster EAACI 2022, Jul 01, 2022

A mechanistic skin immunology model for the support of atopic dermatitis clinical trial design and biomarker programs

Théo Galland, Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Poster QSPC 2022, Apr 21, 2022

Viral kinetic modeling and clinical trial simulation predicts disruption of respiratory disease trials by non-pharmaceutical COVID-19 interventions

Simon Arsène, Alexander Kulesza, Igor Faddeenkov, Théo Galland, Cristhyne Leon
Learn more
Poster QSPC 2022, Apr 20, 2022

A PBPK and immunogenicity model integrated into two disease models

Simon Arsène, Alexander Kulesza, Igor Faddeenkov, Théo Galland, Cristhyne Leon
Learn more
Publication Nature communications, Apr 13, 2022

Modeling the disruption of respiratory disease clinical trials by non-pharmaceutical COVID-19 interventions

Simon Arsène , Claire Couty , Igor Faddeenkov , Natacha Go , Solène Granjeon-Noriot , Daniel Smit , Riad Kahoul , Ben Illigens , Jean-Pierre Boissel , Aude Chevalier , Lorenz Lehr , Christian Pasquali
Learn more
Poster AACR 2022, Apr 12, 2022

Multiscale EGFR mutated NSCLC tumor heterogeneity knowledge-based model predicts tumor growth under Gefitinib: an avenue to in silico clinical trial

M. Duruisseaux1, J-L. Palgen, A. Perrillat-Mercerot, N. Ceres, E. Peyronnet, E. Jacob, R. Kahoul, M. Coudron, M. Poiré, L. Lefevre, R. Toueg, J. Bosley, A. L’Hostis, C. Monteiro
Learn more
Publication Frontiers in Systems Biology: Multiscale Modeling , Mar 07, 2022

Model integration in computational Biology: the Role of reproducibility, credibility and utility

Jonathan Karr, Rahuman S. Malik-Sheriff, James Osborne, Gilberto Gonzalez-Parra, Eric Forgoston, Ruth Bowness, Yaling Liu, Robin Thompson, Winston Garira, Jacob Barhak, John Rice, Marcella Torres, Hana M. Dobrovolny, Tingting Tang, William Waites, James A. Glazier, James R. Faeder and Alexander Kulesza
Learn more
Poster EAACI 2021, Nov 15, 2021

Model based meta-analysis of the effect of non-specific immunomodulation with OM-85 for recurrent viral respiratory tract infections and wheezing: a multi-scale mechanistic approach

Simon Arsène, Alexander Kulesza
Learn more
Poster EAACI 2021, Nov 15, 2021

Application of a mechanistic model to forecast RTI prophylaxis trial feasibility in the post-COVID era

Igor Faddeenkov, Simon Arsène, Alexander Kulesza
Learn more
Poster AASLD conference 2021, Nov 12, 2021

Mechanistic modeling to optimize phase 2b clinical trial design of a new combination therapy for chronic HBV

Solène Granjeon-Noriot1, Anne Schneider1, Emmanuel Peyronnet1, Eulalie Courcelles1, Claire Couty1, Bastien Martin1, Simon Arsène1, Hippolyte Darré1, Evgueni Jacob1, Riad Kahoul1, Hugo Girma2, Marion Odoul2, Isabelle Martin2, Laurène Meyniel-Schicklin2, Dr. Pietro Scalfaro2, Dr. Ben Illigens1,3 and Lara Bruezière1.
Learn more
Poster Iboman 2021, Oct 25, 2021

Application of knowledge-based mechanistic modeling to optimize phase III clinical trials of targeted therapy

A. L’Hostis1, J-L. Palgen1, N. Ceres1, A. Perrillat-Mercerot1, E. Jacob1, R. Kahoul1, M. Coudron1, G. Bouchard1, B.M.W. Illigens1,2, M. Hommel1, J.P. Boissel1, J. Bosley1, C. Monteiro1
Learn more
Publication PLOS One, Oct 11, 2021

Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample

Jean-Pierre Boissel ,David Pérol ,Hervé Décousus ,Ingrid Klingmann ,Marc Hommel
Learn more
Publication PLOS One, Oct 11, 2021

Using numerical modeling and simulation to assess the ethical burden in clinical trials and how it relates to the proportion of responders in a trial sample

Boissel JP, Pérol D, Décousus H, Klingmann I, Hommel M
Learn more
Poster IASLC WCLC 2021, Sep 08, 2021

Multiscale NSCLC tumor growth knowledge based model reproduces tumor non progression under Gefitinib

Adèle L'Hostis, J.-L. Palgen, N. Ceres, E. Peyronnet, A. Perrillat-Mercerot, A. Schneider, M. Margreiter, E. Jacob
Learn more
Poster IASLC WCLC 2021, Sep 08, 2021

Use of a multiscale NSCLC tumor heterogeneity model to predict tumor growth under Gefitinib

Adèle L'Hostis, J.-L. Palgen, N. Ceres, E. Peyronnet, A. Perrillat-Mercerot, A. Schneider, M. Margreiter, E. Jacob
Learn more
Poster ERS 2021, Sep 05, 2021

Mechanistic model based meta-analysis for paediatric respiratory tract infection prophylaxis trial design

Alexander Kulesza, Simon Arsène, Jean-Pierre Boissel
Learn more
Poster PAGE 2021, Aug 18, 2021

In silico clinical trial simulation shows amelioration of ischemia-reperfusion injury in ST-elevation myocardial infarction via inhibition of reactive oxygen species production

B. Martin, E. Courcelles, A. L’Hostis, L. Etheve, E. Bechet, N. Ceres, E. Jacob, E. Peyronnet, B. M.W. Illigens, M. Hommel, J.P. Boissel
Learn more
Publication IEEE Journal of Biomedical and Health Informatics, Jun 23, 2021

Possible contexts of use for in silico trials methodologies: a consensus- based review

Marco Viceconti, Luca Emili, Payman Afshari, Eulalie Courcelles, Cristina Curreli, Nele Famaey, Liesbet Geris, Marc Horner, Maria Cristina Jori, Alexander Kulesza, Axel Loewe, Michael Neidlin, Markus Reiterer, Cecile F. Rousseau, Giulia Russo, Simon J. Sonntag, Emmanuelle M. Voisin, and Francesco Pappalardo
Learn more
Publication CPT: Pharmacometrics & Systems Pharmacology, Jun 08, 2021

Scientific and regulatory evaluation of mechanistic in silico drug and disease models in drug development: building model credibility

Flora T. Musuamba, Ine Skottheim Rusten, Raphaëlle Lesage, Giulia Russo, Roberta Bursi, Luca Emili, Gaby Wangorsch, Efthymios Manolis, Kristin E. Karlsson, Alexander Kulesza, Eulalie Courcelles, Jean-Pierre Boissel, Cécile F. Rousseau, Emmanuelle M. Voisin, Rossana Alessandrello, Nuno Curado, Enrico Dall’ara, Blanca Rodriguez, Francesco Pappalardo, Liesbet Geris
Learn more
Publication Frontiers in Medical Technology: Regulatory Affairs, Feb 24, 2021

Solving the evidence interpretability crisis in health technology assessment: a role for mechanistic models?

Eulalie Courcelles, Jean-Pierre Boissel, Jacques Massol, Ingrid Klingmann, Riad Kahoul, Marc Hommel, Emmanuel Pham and Alexander Kulesza
Learn more
Poster BioSB2020, Oct 27, 2020

In silico clinical trial shows the efficacy of the inhibition of reactive oxygen species production in ST elevated myocardial infarction

Emmanuel Peyronnet; Eulalie Courcelles; Bastien Martin
Learn more
Publication CPT: Pharmacometrics & Systems Pharmacology, Apr 01, 2020

Verifying and Validating Quantitative Systems Pharmacology and In Silico Models in Drug Development: Current Needs, Gaps, and Challenges.

Flora T. Musuamba Roberta Bursi Efthymios Manolis Kristin Karlsson Alexander Kulesza Eulalie Courcelles Jean‐Pierre Boissel Raphaëlle Lesage Cécile Crozatier Emmanuelle M. Voisin Cécile F. Rousseau Thierry Marchal Rossana Alessandrello and Liesbet Geris.
Learn more
Poster AASLD 2019, Nov 08, 2019

An in silico disease model for the development of FXR agonist EYP001 as a therapy for HBV infection

Claudio Monteiro, Lara Bruezière, Samuel Laheux, Marc Hommel, Pauline Radreau, Elise Roy, Raphaël Darteil, Patrice André, Jean-Pierre Boissel, Jacky Vonderscher and Pietro Scalfaro.
Learn more